MeSH term
Frequency | Condition_Probility | Genetic Predisposition to Disease/genetics | 3 | 0.0 |
Genotype | 22 | 0.0 |
Humans | 54 | 0.0 |
Linkage (Genetics)/*genetics | 2 | 0.0 |
Minisatellite Repeats/genetics | 2 | 4.0 |
Pedigree | 2 | 0.0 |
Sialoglycoproteins/*genetics | 18 | 27.0 |
Spondylitis, Ankylosing/*genetics | 2 | 7.0 |
Aged | 15 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
*Chromosomes, Human, Pair 2 | 3 | 1.0 |
Cohort Studies | 3 | 0.0 |
Female | 33 | 0.0 |
Gene Frequency | 13 | 0.0 |
Genetic Predisposition to Disease | 7 | 0.0 |
Haplotypes | 5 | 0.0 |
Interleukin-1/*genetics | 17 | 20.0 |
*Linkage (Genetics) | 2 | 0.0 |
Male | 27 | 0.0 |
Middle Aged | 23 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 45 | 0.0 |
Adult | 24 | 0.0 |
Case-Control Studies | 9 | 0.0 |
Chromosomes, Human, Pair 2 | 3 | 1.0 |
Heterozygote | 4 | 0.0 |
Homozygote | 5 | 0.0 |
Polymerase Chain Reaction | 10 | 0.0 |
*Polymorphism, Genetic | 15 | 0.0 |
Pregnancy | 5 | 0.0 |
Receptors, Interleukin-1/*antagonists & inhibitors | 6 | 17.0 |
Research Support, U.S. Gov't, P.H.S. | 8 | 0.0 |
Base Sequence | 8 | 0.0 |
DNA Primers | 2 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Polymorphism, Genetic | 17 | 0.0 |
Receptors, Interleukin-1/*genetics | 3 | 37.0 |
Amino Acid Sequence | 2 | 0.0 |
Chromosomes, Human, Pair 2/*genetics | 2 | 1.0 |
Molecular Sequence Data | 7 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Adolescent | 6 | 0.0 |
Alleles | 16 | 0.0 |
Child | 6 | 0.0 |
DNA/analysis | 2 | 0.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Linkage Disequilibrium | 6 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Tandem Repeat Sequences | 3 | 2.0 |
Confidence Intervals | 4 | 1.0 |
Odds Ratio | 6 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Interleukin-1/genetics | 3 | 4.0 |
Lupus Erythematosus, Discoid/genetics | 2 | 100.0 |
Tumor Necrosis Factor-alpha/genetics | 4 | 1.0 |
Cytokines/*genetics | 2 | 1.0 |
Variation (Genetics) | 2 | 0.0 |
Animals | 3 | 0.0 |
Introns | 3 | 0.0 |
Spain | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Lymphotoxin/genetics | 2 | 3.0 |
Risk Factors | 4 | 0.0 |
Sialoglycoproteins/genetics | 4 | 13.0 |
Comparative Study | 7 | 0.0 |
Genetic Markers | 4 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Prospective Studies | 2 | 0.0 |
*Multigene Family | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Kidney Failure, Chronic/*genetics | 2 | 13.0 |
Multigene Family | 3 | 0.0 |
Minisatellite Repeats | 2 | 1.0 |
Neoplasm Staging | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Severity of Illness Index | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Proteins/*genetics | 2 | 0.0 |
*Sialoglycoproteins | 2 | 15.0 |
*Variation (Genetics) | 2 | 0.0 |
Prognosis | 2 | 0.0 |
